

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

BLONDER TONGUE LABORATORIES INC

Form: 8-K

Date Filed: 2019-08-14

Corporate Issuer CIK: 1000683

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2019

Blonder Tongue Laboratories, Inc.
(Exact Name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

1-14120
(Commission File Number)

52-1611421
(I.R.S. Employer
Identification No.)

One Jake Brown Road, Old Bridge, New Jersey 08857
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (732) 679-4000

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
|--------------------------------|-------------------|---|
| Common Stock, par value \$.001 | BDR | NYSE American |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition

On August 14, 2019, Blonder Tongue Laboratories, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2019. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information disclosed in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits. The following exhibit is filed herewith:

| Exhibit No. | Description |
|--------------------|--|
| 99.1 | Press Release dated August 14, 2019. |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BLONDER TONGUE LABORATORIES, INC.

By: */s/ Eric Skolnik*

Eric Skolnik

Senior Vice President and Chief Financial Officer

Date: August 14, 2019

EXHIBIT INDEX

Exhibit No. **Description**

99.1 [Press Release dated August 14, 2019.](#)



FOR IMMEDIATE RELEASE:

Blonder Tongue Reports Second Quarter 2019 Results

OLD BRIDGE, NJ / August 14, 2019 / Blonder Tongue Laboratories, Inc. (NYSE American: **BDR**) announced its sales and results for the second quarter and six months ended June 30, 2019.

Net sales increased \$160,000 or 3.0% to \$5,437,000 for the second quarter of 2019 from \$5,277,000 for the comparable period in 2018. Net loss for the three months ended June 30, 2019 was \$(891,000) or \$(0.09) per share, compared to \$(335,000) or \$(0.04) per share for the comparable period in 2018.

The increase in sales was primarily attributed to an increase in sales of set top box products and NeXgen Gateway ("NXG") products, offset by a decrease in sales of data products, digital video headend products, contract manufactured products and HFC distribution products. Sales of set top box products were \$1,002,000 and zero, NXG products were \$362,000 and zero, data products were \$565,000 and \$1,055,000, digital video headend products were \$2,244,000 and \$2,542,000, contract manufactured products were \$46,000 and \$155,000 and HFC distribution products were \$581,000 and \$761,000 in the second three months of 2019 and 2018, respectively.

For the six months ended June 30, 2019, net sales decreased \$1,121,000, or 10.5%, to \$9,519,000 in 2019 from \$10,640,000 in 2018. Net earnings for the six months ended June 30, 2019 was \$4,434,000 or \$0.44 per diluted share, compared to \$(398,000) or \$(0.05) per diluted share for the comparable period in 2018.

The decrease in sales was primarily attributed to a decrease in sales of data products and digital video headend products, offset by an increase in sales of set top box products. Sales of data products were \$1,105,000 and \$2,454,000, digital video headend products were \$4,190,000 and \$5,085,000 and set top box products were \$1,193,000 and zero in the first six months of 2019 and 2018, respectively.

Commenting on the six month results, Chief Executive Officer Robert J. Pallé noted, "Although sales in the second quarter of 2019 showed a 3% increase over sales in the second quarter of 2018, and a 33% increase over the first quarter of 2019, we are disappointed in the amount of the increase and the resulting financial performance. We are taking steps to address these issues by making adjustments to our operating expenses so that they better align with our current sales forecast, and by increasing the intensity of our new product sales initiatives. Despite the second quarter and year-to-date performance, we are pleased with the early responses to both our IPTV set top box and NeXgen Gateway introductions. We anticipate that these initiatives will be the catalyst for an increase in sales in future periods."



Conference Call Reminder

Details of the live teleconference:

Date: Wednesday, August 14, 2019

Time: 11:00 a.m. Eastern Time (10:00 a.m. CT, 8:00 a.m. PT)

Investor Dial-in (US & Canada Toll-Free): 877-407-8033

The audio replay will be available under [Investor Related Information](#) on the Blonder Tongue Investor Relations webpage.

About Blonder Tongue

Blonder Tongue Laboratories, Inc. is one of the oldest designers and manufacturers of cable television and video transmission technology in the USA, with most of our products continuing to be designed and built in our state-of-the-art New Jersey factory for almost 50 years. We offer US based engineering and manufacturing excellence with an industry reputation of delivering ultra-high reliability products. As a leader in cable television systems design, the Company provides service operators and systems integrators with comprehensive solutions for the management and distribution of digital video, IPTV and high-speed data services, as well as RF broadband distribution over coax, fiber and IP networks for homes and businesses. Additional information on the Company and its products can be found at www.blondertongue.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The information set forth above includes "forward-looking" statements and accordingly, the cautionary statements contained in Blonder Tongue's Annual Report and Form 10-K for the year ended December 31, 2018 (See Item 1: Business, Item 1A: Risk Factors, Item 3: Legal Proceedings and Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations), and other filings with the Securities and Exchange Commission are incorporated herein by reference. The words "believe", "expect", "anticipate", "project", "target", "intend", "plan", "seek", "estimate", "endeavor", "should", "could", "may" and similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to projections for our future financial performance, our anticipated growth trends in our business and other characterizations of future events or circumstances are forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. Blonder Tongue undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Blonder Tongue's actual results may differ from the anticipated results or other expectations expressed in Blonder Tongue's "forward-looking" statements.

Contacts

Eric Skolnik
Chief Financial Officer
eskolnik@blondertongue.com
(732) 679-4000

Robert J. Pallé
Chief Executive Officer
bpalle@blondertongue.com
(732) 679-4000



Blonder Tongue Laboratories, Inc.
Condensed Consolidated Summary of Operating Results
(unaudited, in thousands, except per share data)

| | Three months ended | | Six months ended | |
|---|--------------------|-----------|------------------|-----------|
| | June 30, | | June 30, | |
| | 2019 | 2018 | 2019 | 2018 |
| Net sales | \$ 5,437 | \$ 5,277 | \$ 9,519 | \$ 10,640 |
| Gross profit | 2,005 | 2,191 | 3,096 | 4,414 |
| Loss from operations | (845) | (217) | (2,612) | (130) |
| Net (loss) earnings | \$ (891) | \$ (335) | \$ 4,434 | \$ (398) |
| Basic net (loss) earnings per share | \$ (0.09) | \$ (0.04) | \$ 0.46 | \$ (0.05) |
| Diluted net (loss) earnings per share | \$ (0.09) | \$ (0.04) | \$ 0.44 | \$ (0.05) |
| Basic weighted average shares outstanding | 9,611 | 8,905 | 9,558 | 8,560 |
| Diluted weighted average shares outstanding | 9,611 | 8,905 | 10,065 | 8,560 |

Blonder Tongue Laboratories, Inc
Condensed Consolidated Summary Balance Sheets
(in thousands)

| | (unaudited) | |
|--|------------------|----------------------|
| | June 30, 2019 | December 31, 2018 |
| Current assets | \$ 12,295 | \$ 10,377 |
| Property, plant and equipment, net | 271 | 2,890 |
| Total assets | 18,786 | 15,601 |
| Current liabilities | 3,682 | 8,263 |
| Long-term liabilities | 2,984 | 171 |
| Stockholders' equity | 12,120 | 7,167 |
| Total liabilities and stockholders' equity | \$ 18,786 | \$ 15,601 |